Prophylaxis against infective endocarditis: summary of NICE guidance

doi:10.1136/bmj.39510.423148.AD

BMJ 2008;336:770-771 (5 April), doi:10.1136/bmj.39510.423148.AD

Practice

Guidelines

Prophylaxis against infective endocarditis: summary of NICE guidance

Roberta Richey, technical analyst¹, David Wray, professor of oral medicine², Tim Stokes, associate director¹, on behalf of the Guideline Development Group

¹ National Institute for Health and Clinical Excellence, Manchester M1 4BD, ² Glasgow Dental School, Glasgow G2 3JZ

Correspondence to: D Wray d.wray@dental.gla.ac.uk

The first 150 words of the full text of this article appear below.

Why read this summary?

Infective endocarditis is a rare condition with a high mortalityand morbidity. Accepted clinical practice has been to use antibioticprophylaxis in those at risk of infective endocarditis who arehaving dental and certain non-dental interventional procedures,in the belief that this may prevent the development of infectiveendocarditis. The effectiveness of such antibiotic prophylaxisin humans is, however, not proved¹ and recent internationalguidelines recommend a much more limited role for antibioticprophylaxis against infective endocarditis. This article summarisesthe most recent guidance from the National Institute for Healthand Clinical Excellence (NICE) on antibiotic prophylaxis againstinfective endocarditis.²

Recommendations

NICE recommendations are based on systematic reviews of bestavailable evidence. When minimal evidence is available recommendationsare based on the guideline development group’s opinionof what constitutes good practice. With a serious rare condition,such as infective endocarditis, research using experimentalstudy designs is difficult and the evidence base . . . [Full text of this article]

Identifying cardiac risk factors
Patient advice
Prophylaxis for patients at risk of infective endocarditis

Overcoming barriers

Further information on the guidance
Background
Methods
Key areasof uncertainty needing further research
Guidelinedevelopment group

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

Technorati What's this?

A call for national monitoring of antibiotic prophylaxis: Neil Herring and David C Sprigings
BMJ 2008 336: 976. [Extract] [Full Text] [PDF]

Commentary: Controversies in NICE guidance on infective endocarditis: Mark Connaughton
BMJ 2008 336: 771. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

Herring, N., Sprigings, D. C (2008). A call for national monitoring of antibiotic prophylaxis. BMJ 336: 976-976 [Full text]

Rapid Responses:

Read all Rapid Responses

Infective endocarditis and IV drug users: Dr Arun Viswanath, et al.
bmj.com, 5 Apr 2008 [Full text]
NICE guidance on prophylaxis of endocarditis need further debate: David C Shanson
bmj.com, 10 Apr 2008 [Full text]
NICE guidance on prophylaxis against infective endocarditis: Some potential problems.: John O'Sullivan, et al.
bmj.com, 12 Apr 2008 [Full text]
NICE Guidelines on antibiotic prophylaxis against infective endocarditis: A call for national monitoring of outcome: Neil Herring, et al.
bmj.com, 20 Apr 2008 [Full text]
Prophylaxis against Infective Endocarditis:NICE Guidelines: David R Ramsdale, et al.
bmj.com, 24 Apr 2008 [Full text]
NICE Guideline on Prophylaxis against Infective Endocarditis: guideline developer's response: David Wray, et al.
bmj.com, 13 Jun 2008 [Full text]
NICE confusion between cost-effectiveness and research: Raj Mohindra
bmj.com, 1 Jul 2008 [Full text]